Source: Asian Venture Capital Journal

ZG Biotech: Shanghai CDMO player gets $51m Series A

Zhenge Biotech - a Shanghai-based contract development and manufacturing organization (CDMO) for large molecule drugs - has raised $51 million in Series A funding led by Lyfe Capital.

Read full article »

ZG Biotech's Competitors | ZG Biotech's News | ZG Biotech's Financials

Followers on Owler

Est. Annual Revenue

$5.0-25M

Est. Employees

100-250

Chairman & CEO

Jianxin Chen

CEO Approval Rating

90/100

ZhenGe Biotech is a China-based contract development organization that provides services such as clinical research and cell line development for the pharmaceutical industry.